GlobeNewswire Inc.··Hagens BermanSoleno's VYKAT XR Faces Legal Storm as Safety Concerns Tank Stock 40%
Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.
SLNOstock declinesecurities class action